Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 600-609

  Casarosa, Paola ^a   Kollak, Ines ^a   Kiechle, Tobias ^a   Ostermann, Angela ^a   Schnapp, Andreas ^a   Kiesling, Ralf ^a   Pieper, Michael ^a   Sieger, Peter ^a   Gantner, Florian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BI 744CL; FENOTEROL; FORMOTEROL; ISOPRENALINE; OLODATEROL; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG RECEPTOR BINDING; HALF LIFE TIME; HUMAN; HUMAN CELL; LIPID BILAYER; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANIMALS; ASTHMA; BENZOXAZINES; BINDING SITES; BRONCHODILATOR AGENTS; CRICETINAE; ETHANOLAMINES; HALF-LIFE; HUMANS; LIPID BILAYERS; MICE; MICE, INBRED BALB C; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 79956212667     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179259     Document Type: Article

References (30)

1. Anderson GP, Lindén A, and Rabe KF (1994) Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7:569-578. (Pubitemid 24099018)
2. Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144:317-322.
3. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, and Skidmore IF (1991) Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104:665-671.
4. Bender BG (2002) Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 109:S554-S559.
5. Bergendal A, Lindén A, Skoogh BE, Gerspacher M, Anderson GP, and Löfdahl CG (1996) Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Br J Pharmacol 117:1009-1015. (Pubitemid 26105322)
6. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, and Schnapp A (2010) Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 334:53-62.
7. Braman SS (2006) The global burden of asthma. Chest 130:4S-12S.
8. Casarosa P, Waldhoer M, LiWang PJ, Vischer HF, Kledal T, Timmerman H, Schwartz TW, Smit MJ, and Leurs R (2005) CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J Biol Chem 280:3275-3285. (Pubitemid 40223789)
9. Cazzola M and Matera MG (2008) Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155:291-299.
10. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Green SA, Spasoff AP, Coleman RA, Johnson M, and Liggett SB (1996) Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 271:24029-24035.
12. Green SA, Turki J, Bejarano P, Hall IP, and Liggett SB (1995) Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13:25-33.
13. Guerra S (2009) Asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 9:409-416.
14. Hill AV (1909) The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients. J Physiol 39:367-373.
15. Johnson EN and Druey KM (2002) Heterotrimeric G protein signaling: role in asthma and allergic inflammation. J Allergy Clin Immunol 109:592-602. (Pubitemid 34327182)
16. Johnson M (1995) Salmeterol. Med Res Rev 15: 225-257.
17. Johnson M, Butchers PR, Coleman RA, Nials AT, Strong P, Sumner MJ, Vardey CJ, and Whelan CJ (1993) The pharmacology of salmeterol. Life Sci 52:2131-2143.
18. Lemoine H (1992) Beta adrenoceptor ligands: characterization and quantification of drug effects. Quant Struct-Act Relat 11:211-218.
19. Löfdahl CG and Svedmyr N (1989) Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 44:264-271.
20. O'Byrne PM, van der Linde J, Cockcroft DW, Gauvreau GM, Brannan JD, Fitzgerald M, Watson RM, Milot J, Davis B, O'Connor M, et al. (2009) Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma. J Allergy Clin Immunol 124:1217-1221.
21. Pauwels RA and Rabe KF (2004) Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364:613-620.
22. Perera BJ (2003) Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths. Ceylon Med J 48:99.
23. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, et al. (2011) Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469:175-180.
24. Rhodes DG, Newton R, Butler R, and Herbette L (1992) Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol 42:596-602. (Pubitemid 23027621)
25. Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, and Trevethick M (2008) A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. J Pharmacol Toxicol Methods 58:189-197.
26. Tamura G and Ohta K (2007) Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 101:1895-1902. (Pubitemid 47163538)
27. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, and UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554.
28. Teschemacher A and Lemoine H (1999) Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 288:1084-1092. (Pubitemid 29254145)
29. Van Noord JA, Korducki L, Hamilton AL, and Koker P (2009) Four weeks once daily treatment with BI 1744 CL, a novel long-acting 2-agonist, is effective in COPD patients. Am J Respir Crit Care Med 179:A6183.
30. Waldeck B (2002) Beta-adrenoceptor agonists and asthma - 100 years of development. Eur J Pharmacol 445:1-12.